| Notes |
History
The Broad Institute evolved from a decade of research collaborations among MIT and Harvard scientists.[3] One cornerstone was the Center for Genome Research of Whitehead Institute at MIT. Founded in 1982, the Whitehead became a major center for genomics and the Human Genome Project. As early as 1995, scientists at the Whitehead started pilot projects in genomic medicine, forming an unofficial collaborative network among young scientists interested in genomic approaches to cancer and human genetics. Another cornerstone was the Institute of Chemistry and Cell Biology established by Harvard Medical School in 1998 to pursue chemical genetics as an academic discipline.[4] Its screening facility was one of the first high-throughput resources opened in an academic setting. It facilitated small molecule screening projects for more than 80 research groups worldwide.
To create a new organization that was open, collaborative, cross-disciplinary and able to organize projects at any scale, planning took place in 2002–2003 among philanthropists Eli and Edythe Broad, MIT, the Whitehead Institute, Harvard and the Harvard-affiliated hospitals (in particular, the Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Children's Hospital Boston, the Dana-Farber Cancer Institute and the Massachusetts General Hospital).
The Broads made a founding gift of $100 million and the Broad Institute was formally launched in May 2004. In November 2005, the Broads announced an additional $100 million gift to the institute.[5] On September 4, 2008, the Broads announced an endowment of $400 million to make the Broad Institute a permanent establishment.[6] In November 2013, they invested an additional $100 million to fund a second decade of research at the institute.[7]
During the COVID-19 pandemic in the United States, the Broad Institute ran laboratory tests for the virus for about 100 colleges and universities in the northeastern U.S.[8]
|